| Therapeutic drug monitoring of oral targeted antineoplastic drugs A Mueller-Schoell, SL Groenland, O Scherf-Clavel, M van Dyk, ... European journal of clinical pharmacology 77, 441-464, 2021 | 162 | 2021 |
| Plasma extracellular nanovesicle (exosome)‐derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure A Rowland, W Ruanglertboon, M Van Dyk, D Wijayakumara, LS Wood, ... British journal of clinical pharmacology 85 (1), 216-226, 2019 | 76 | 2019 |
| Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure A Rowland, M Van Dyk, AA Mangoni, JO Miners, RA McKinnon, ... Expert Opinion on Drug Metabolism & Toxicology 13 (1), 31-49, 2017 | 63 | 2017 |
| Perspectives on model‐informed precision dosing in the digital health era: challenges, opportunities, and recommendations F Kluwe, R Michelet, A Mueller‐Schoell, C Maier, L Klopp‐Schulze, ... Clinical Pharmacology & Therapeutics 109 (1), 29-36, 2021 | 46 | 2021 |
| Exploring the use of serum‐derived small extracellular vesicles as liquid biopsy to study the induction of hepatic cytochromes P450 and organic anion transporting polypeptides AD Rodrigues, M Van Dyk, MJ Sorich, A Fahmy, Z Useckaite, LA Newman, ... Clinical Pharmacology & Therapeutics 110 (1), 248-258, 2021 | 43 | 2021 |
| Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure A Rowland, M Van Dyk, AM Hopkins, R Mounzer, TM Polasek, ... Clinical Pharmacology & Therapeutics 104 (6), 1219-1228, 2018 | 33 | 2018 |
| Efficacy and safety of NSAIDs in infants: a comprehensive review of the literature of the past 20 years VC Ziesenitz, T Welzel, M van Dyk, P Saur, M Gorenflo, JN van den Anker Pediatric Drugs 24 (6), 603-655, 2022 | 30 | 2022 |
| Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries M Van Dyk, JC Marshall, MJ Sorich, LS Wood, A Rowland European journal of clinical pharmacology 74, 913-920, 2018 | 24 | 2018 |
| A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: a platform for optimised KI dosing M Van Dyk, JO Miners, G Kichenadasse, RA McKinnon, A Rowland Journal of Chromatography B 1033, 17-26, 2016 | 21 | 2016 |
| Targeted arginine metabolomics: A rapid, simple UPLC-QToF-MSE based approach for assessing the involvement of arginine metabolism in human disease M Van Dyk, AA Mangoni, M McEvoy, JR Attia, MJ Sorich, A Rowland Clinica Chimica Acta 447, 59-65, 2015 | 18 | 2015 |
| Evaluation of modafinil as a perpetrator of metabolic drug–drug interactions using a model informed cocktail reaction phenotyping trial protocol A Rowland, M Van Dyk, D Warncken, AA Mangoni, MJ Sorich, A Rowland British journal of clinical pharmacology 84 (3), 501-509, 2018 | 15 | 2018 |
| Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of … AM Hopkins, M Van Dyk, A Rowland, MJ Sorich Pigment cell & melanoma research 32 (4), 576-583, 2019 | 12 | 2019 |
| Use of physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in axitinib exposure: a fresh approach to … MJ Sorich, F Mutlib, M van Dyk, AM Hopkins, TM Polasek, JC Marshall, ... The Journal of Clinical Pharmacology 59 (6), 872-879, 2019 | 12 | 2019 |
| Steady-state pharmacokinetics of phentermine extended-release capsules. G Groenewoud, R Schall, HK Hundt, FO Müller, M Van Dyk International Journal of Clinical Pharmacology, Therapy, and Toxicology 31 …, 1993 | 10 | 1993 |
| Combining therapeutic drug monitoring and pharmacokinetic modelling deconvolutes physiological and environmental sources of variability in clozapine exposure KH Wills, SJ Behan, MJ Nance, JL Dawson, TM Polasek, AM Hopkins, ... Pharmaceutics 14 (1), 47, 2021 | 9 | 2021 |
| Validation of a 3-h sampling interval to assess variability in cytochrome P450 3A phenotype and the impact of induction and mechanism-based inhibition using midazolam as a … M Van Dyk, AJ Kapetas, AM Hopkins, AD Rodrigues, M Vourvahis, ... Frontiers in Pharmacology 10, 1120, 2019 | 6 | 2019 |
| Physiologically-based pharmacokinetic modeling as an approach to evaluate the effect of covariates and drug-drug interactions on variability in epidermal growth factor receptor … M Van Dyk, A Rowland Translational Cancer Research 6 (Suppl 10), 2017 | 6 | 2017 |
| PBPK modeling as an approach to evaluate the effect of covariates and drug-drug interactions on variability in EGFR kinase inhibitor exposure. Transl M Van Dyk, A Rowland Cancer Res 6, S1600-S1615, 2017 | 6 | 2017 |
| Investigation of a possible pharmacokinetic interaction between nisoldipine and quinidine in healthy volunteers R Schall, FO Müller, G Groenewoud, HKL Hundt, HG Luus, M van Dyk, ... Drug Investigation 8, 162-170, 1994 | 6 | 1994 |
| Simulation-based assessment of the impact of non-adherence on endoxifen target attainment in different tamoxifen dosing strategies A Mueller-Schoell, L Klopp-Schulze, R Michelet, M van Dyk, TE Mürdter, ... Pharmaceuticals 14 (2), 115, 2021 | 5 | 2021 |
